A comprehensive assessment using COPD assessment test scoring and modified Medical Research Council dyspnea scoring is necessary for personalized therapy for COPD patients

Dear editor

In a recent issue of the International Journal of COPD, Rhee et al have demonstrated considerable discrepancies between modified Medical Research Council (mMRC) dyspnea scoring and COPD assessment test (CAT) scoring in patients with COPD. The current data are also supported by the findings described in another article, which indicates that more than 50% of COPD patients show discrepancies between the severity of CAT scores and that of mMRC scores in the real world.

In principle, CAT and mMRC scores are not correlated. The CAT scoring is for continuous variables, while mMRC scoring is for categorical variables. Furthermore, the severity of CAT scores is not correlated with that of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging. Because CAT scoring is based on eight different items, the sleep disturbance score is not correlated with the cough/sputum symptom score or with the exertional dyspnea score. This justifies the discrepancy found between the scores in the two scoring systems.

The study by Rhee et al strongly indicates that comprehensive assessment using both the CAT and the mMRC dyspnea scoring systems is necessary for personalized therapy for COPD patients. The evaluation of health status and the assessment of dyspnea severity suggest the different aspects of pathophysiology of COPD patients. However, there is a problem in COPD practice and research at the current juncture. By searching PubMed literature of the past 5 years using keywords “CAT” and “COPD”, 280 papers were extracted. However, a search using the keywords “mMRC” and “COPD” extracted less than half this number (135 papers). Unfortunately, a search using all keywords “CAT”, “mMRC”, and “COPD” extracted very few papers (46 papers, 16.4% of the number of papers extracted using the search terms “CAT” and “COPD”). Therefore, it is reasonable to speculate that mMRC and CAT assessment may not be performed simultaneously for the assessment of COPD patients in clinical practice.

The CAT and mMRC scores are affected differently by bronchodilator therapy in COPD patients. Ohno et al demonstrated that a novel, once-daily inhaled long-acting beta 2-agonist, indacaterol, improved pulmonary function variables, mMRC dyspnea scale score, and CAT scores. However, a switch in replacement therapy from salmeterol to indacaterol significantly improved the mMRC and forced vital capacity

Shinji Teramoto, Toshihide Inui, Nobuyuki Hizawa

1Department of Pulmonary Medicine, Hitachinaka Medical Education and Research Center, University of Tsukuba, Ibaraki, Japan; 2Department of Pulmonary Medicine, Hitachinaka General Hospital, Hitachi Ltd, Ibaraki, Japan; 3Department of Pulmonary Medicine, Graduate School of Comprehensive Human Science, University of Tsukuba, Ibaraki, Japan

Correspondence: Shinji Teramoto
Hitachinaka Medical Education and Research Center, University of Tsukuba, 20-1 Hitachinaka-shi, Ishikawa-cho, Ibaraki, 312-0057, Japan
Tel +81 29 354 5111
Fax +81 29 354 5926
Email shinjit-sky@umin.ac.jp
values, but did not significantly improve the CAT scores or other pulmonary function variables.\textsuperscript{3}

Importantly, mMRC and CAT assessments can be used to predict the prognosis of COPD patients. The COPD History Assessment in Spain (CHAIN) study revealed that the CAT could be used for predicting all-cause mortality in patients with COPD, but was inferior to mMRC dyspnea scores in this respect.\textsuperscript{4} COPD patients who died had higher CAT and MRC dyspnea scores than survivors. Unfortunately, the CHAIN study used original MRC scores instead of mMRC scores.

When personalized therapy for different phenotypes of COPD is implemented, bidirectional assessment using CAT and mMRC scoring will be necessary in clinical settings, in addition to assessment of pulmonary function and presence of inflammatory indicators in exhaled breath, sputum, and blood.

Disclosure
The authors report no conflicts of interest in this communication.

References
1. Rhee CK, Kim JW, Hwang YI, et al. Discrepancies between modified Medical Research Council dyspnea score and COPD assessment test score in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1623–1631.
2. Price DB, Baker CL, Zou KH, Higgins VS, Bailey JT, Pike JS. Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. Int J Chron Obstruct Pulmon Dis. 2014;9:551–561.
3. Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Int J Chron Obstruct Pulmon Dis. 2014;9:107–114.
4. Casanova C, Marin JM, Martinez-Gonzalez C, et al; COPD History Assessment in Spain (CHAIN) Cohort. Differential effect of modified Medical Research Council dyspnea, COPD Assessment Test, and clinical COPD questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD. Chest. 2015;148:159–168.
Dear editor,

In a recent letter to the Editor of the International Journal of COPD, Teramoto et al suggested bidirectional assessment using the COPD assessment test (CAT) and the modified Medical Research Council (mMRC) dyspnea score in COPD patients. However, there may be two questions regarding this suggestion. Do clinicians measure two different scores for all COPD patients? Can one score replace the other score? To help answer these questions, we have further analyzed our cohort data of previous publication (Korean COPD Subtype Study [KOCOSS] cohort, n=790). In our previous study, we showed that there was discrepancy between the CAT and mMRC scoring systems. We have further analyzed if there was still discrepancy between CAT score for breathlessness and mMRC dyspnea score. The fourth question in the CAT is a score for breathlessness when the patient walks up a hill or one flight of stairs. Since both the mMRC and the fourth CAT score are questions regarding dyspnea, it is expected that there may be close correlation between these two scores. If this is the case, the mMRC score may be replaced by the fourth CAT score.

However, there was still discrepancy between the CAT score for breathlessness and the mMRC dyspnea score. Interestingly, a histogram of the fourth CAT score according to the mMRC showed wide variation in the CAT score for breathlessness in each mMRC group (Figure 1). Moreover, the percentage of CAT score for breathlessness in each mMRC group was also variable (Figure 2). For example, among patients with mMRC score of 0 (n=69), 14.5% of patients (n=10) scored (marked) 3 point in fourth CAT question.

Despite the discrepancies, the fourth CAT score and mMRC score are similar questions regarding dyspnea; however, the answers for these two questions were different. This is a rather surprising result, because mMRC is an indicator of breathlessness. Also, this result could suggest

![Figure 1](https://example.com/figure1.png)

Figure 1 Histogram of CAT scores for breathlessness according to mMRC score. 
Abbreviations: CAT, COPD assessment test; mMRC, modified Medical Research Council.
that CAT score for breathlessness cannot be identical with mMRC score and that it cannot be used as a surrogate for the mMRC score.

In conclusion, there was still discrepancy evident, even between the fourth CAT score and the mMRC score. Therefore, CAT score for breathlessness cannot replace mMRC score.

Disclosure

The author reports no conflicts of interest in this communication.

Reference

1. Rhee CK, Kim JW, Hwang YI, et al. Discrepancies between modified Medical Research Council dyspnea score and COPD assessment test score in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1623–1631.